First Quarter 2015 Net Sales Figures for Arzerra®

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
First Quarter 2015 Net Sales Figures for Arzerra® (Ofatumumab)

Company Announcement

  • Worldwide net sales of Arzerra ® in Q1 2015 totaled GBP 11.1 million
  • Genmab expects royalty payment of approximately DKK 22 million

Copenhagen, Denmark; May 6, 2015 – Genmab A/S (OMX: GEN) announced today that net sales of Arzerra (ofatumumab) by GlaxoSmithKline and Novartis during the first quarter of 2015 were GBP 11.1 million (approximately DKK 111 million). This figure consists of net sales in the US of GBP 6.0 million and in the rest of the world of GBP 5.1 million.  Under the terms of the collaboration with Novartis Pharma AG, Genmab expects to receive a royalty payment of approximately DKK 22 million.

The conversion from GBP to DKK has been made using the Danish Central Bank average rates for the first quarter of 2015.

About Arzerra Arzerra (ofatumumab) is a human monoclonal antibody that is designed to target the CD20 molecule found on the surface of chronic lymphocytic leukemia (CLL) cells and normal B lymphocytes.

In the United States, Arzerra is approved for use in combination with chlorambucil for the treatment of previously untreated patients with CLL for whom fludarabine-based therapy is considered inappropriate. In the European Union, Arzerra is approved for use in combination with chlorambucil or bendamustine for the treatment of patients with CLL who have not received prior therapy and who are not eligible for fludarabine-based therapy. 

In more than 50 countries worldwide, Arzerra is also indicated as monotherapy for the treatment of patients with CLL who are refractory after prior treatment with fludarabine and alemtuzumab.

Arzerra is marketed under a co-development and collaboration agreement between Genmab and Novartis, as successor in interest to GSK.

About Genmab Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.  Founded in 1999, the company currently has one marketed antibody, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and daratumumab in clinical development for multiple myeloma and non-Hodgkin’s lymphoma, in addition to other clinical programs, and an innovative pre-clinical pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. Genmab's deep antibody expertise is expected to provide a stream of future product candidates.  Partnering of selected innovative product candidates and technologies is a key focus of Genmab’s strategy and the company has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com .

Contact:           Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com . Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law. Genmab A/S and its subsidiaries own the following trademarks: Genmab ® ; the Y-shaped Genmab logo ® ; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo™; the HexaBody logo™; HuMax ® ; HuMax-CD20 ® ; DuoBody ® ; HexaBody ® and UniBody ® . Arzerra ® is a trademark of Novartis Pharma AG. 

Company Announcement no. 19 CVR no. 2102 3884

Genmab A/S Bredgade 34E 1260 Copenhagen K Denmark

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Yatsen’s November 25 Report Is the Real Beauty Test

Updated Category News Views 0

Beauty shelves can hide a lot of sins, but earnings day tends to drag them into fluorescent light. Yatsen will release unaudited third-quarter 2026 financial results before the U.S. market opens on Wednesday, November 25, then management will take questions at 7:30 a.m. Eastern Time. For anyone following NYSE:YSG, this is not a results story yet. It is a calendar marker,...

Continue Reading
Zunyi’s History Tour Carries China’s Story Overseas

Updated Category News Views 46

China’s national story does not travel overseas by accident; it gets carried by visitors, monuments, rail lines, rivers and carefully chosen questions. The Zunyi News and Media Center report follows Tayyab, a Pakistani PhD student in aerospace engineering at Peking University, as he heads from Beijing to Zunyi, Guizhou, carrying a copy of Edgar Snow’s Red Star Over...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 49

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading
Exiger's CEO Honored for Military Support Excellence

Updated Category News Views 118

Recognizing Civilian and Military Leadership When you hear "recognition in the military sector," it isn't just a pat on the back. It's a whole parade of brass hats and high-flyers giving their nods. So, November 10th wasn't just any regular day—Brandon Daniels, CEO of Exiger, gets a shiny, prestigious Five-Star Award for his "extraordinary support" of our military...

Continue Reading
Photocure Opens a New Access Route for Hexvix Patients

Updated Category News Views 25

Forty-plus markets just moved from “not available” toward a workable route for individual bladder cancer patients, and that is the real substance of Photocure’s new arrangement with Clinigen. This is not a sweeping product launch, nor is it an approval announcement dressed up in confetti. It is a Named Patient Program, which matters because the regulatory plumbing...

Continue Reading
Benicia's Bold Move to Streamline Permitting Pays Off

Updated Category News Views 171

Award-Winning Innovation from Benicia Benicia, California, shoots ahead of the pack by scooping up a highly coveted Helen Putnam Award for Excellence. Why? They chopped down bureaucracy like a lumberjack with a new ax by ushering in a digital revolution for their permitting process. Make no mistake, folks, this ain’t just a pat on the back—it's a blueprint for cities...

Continue Reading
Unilumin's APEC 2026 Showcase Is a Useful Field Test

Updated Category News Views 65

Few sales pitches get stress-tested by a thousand journalists, a major airport, and a leaders' summit all at once. That is the useful part of Unilumin's role as an official sponsor of APEC 2026 in Shenzhen. The company says its LED systems were installed across summit venues, the media center, transportation hubs, and city landmarks as the 33rd APEC Economic Leaders'...

Continue Reading
CATL Makes Its APEC Case Beyond the Electric Car Market

Updated Category News Views 10

A 99-Second Pitch With Bigger Ambitions Battery swapping got a rare moment in the geopolitical sunlight at Shenzhen's APEC CEO Summit, and CATL was plainly trying to make that moment count. Dr. Robin Zeng, the company's founder, chairman and chief executive, used the opening business dialogue to argue that the Asia-Pacific region holds more opportunity than trouble. Fair...

Continue Reading
Diwali at Heritage Shows the Real Estate Community Test

Updated Category News Views 89

Fireworks do not sell a townhome by themselves, but belonging can sure help close the distance between a brochure and a serious purchase. Heritage at South Brunswick recently held a Diwali celebration sponsored by American Properties at South Brunswick LLC, bringing homeowners, families, and the builder's team into the same room for an evening of food, music, dancing,...

Continue Reading
Vertiv's 800 VDC Push Gives AI Builders More Choices

Updated Category News Views 321

Electricity is becoming the awkward roommate inside every serious AI buildout, and Vertiv is trying to move it out of the rack before it eats the whole house. The company has expanded its 800 VDC offering beyond the PowerDirect 5000 rack product introduced in May 2026, laying out systems for the rack, the AI compute pod, and the full data hall. For investors following...

Continue Reading

Top 5 Most Recently Viewed Articles

Future Prospects of the Aluminum Die Casting Machine Market

Updated Category News Views 293

Growing Demand for Aluminum Die Casting Machines The Aluminum Die Casting Machine market is set to experience notable growth, with expectations to reach a significant market value of around $4.2 billion soon. Projections indicate that this sector could expand at a compound annual growth rate (CAGR) of 6.5% over the upcoming years, potentially hitting approximately $7.3...

Continue Reading
Upcoming Class Action Against Match Group, Inc. (MTCH)

Updated Category News Views 160

Upcoming Class Action Against Match Group, Inc. (MTCH) The Gross Law Firm recently announced a class action notice aimed at shareholders of Match Group, Inc. (NASDAQ: MTCH). This notice serves as an important call to action for shareholders who purchased shares during a specified class period. The firm encourages these individuals to reach out regarding their potential...

Continue Reading
Unveiling Hidden Treasures of Giza at Cosmic Summit 2025

Updated Category News Views 589

Unveiling Hidden Treasures of Giza at Cosmic Summit 2025 Get ready for an exciting event that promises to shed light on groundbreaking findings beneath the iconic Pyramids of Giza! The Cosmic Summit 2025 presents an exclusive opportunity for journalists to engage with distinguished researchers from the Khafre Research Project. Their innovative use of acoustic and radar...

Continue Reading
Impacts of Recent Class Action on WPP plc Investors' Rights

Updated Category News Views 251

Understanding the Class Action Against WPP plc Recently, a significant class action lawsuit has been initiated against WPP plc (NYSE: WPP), raising important issues for its shareholders. The accusations suggest that the company's leadership misrepresented the reliability of its revenue forecasts and growth potential, all while downplaying risks associated with...

Continue Reading
Texaf Secures EUR 5.39 Million for Sustainable Development

Updated Category News Views 47

Texaf's Strategic Development in Urban Infrastructure Texaf is taking significant strides in urban development with its recent project, the Petit-Pont building. The company is set to benefit from a substantial investment of EUR 5.39 million coming from the SFA Congo and African Rivers Fund IV LP. This initiative not only reflects Texaf's commitment to enhancing...

Continue Reading